Prime Medicine (PRME) closed at $4.27 on November 13, 2026, up 9.8% from the previous close, on volume of 5,845,389 shares (30-day average 5,740,932).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 12, 2026 | Call Spread | 21-Jan-282 : 5 C | 1,704 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Prime Medicine closes $143.7 million stock offering with full underwriter option exercised
Market Chameleon (Fri, 13-Nov 10:15 AM ET)
BMO Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)
TipRanks (Fri, 13-Nov 11:55 AM ET)
TipRanks (Fri, 13-Nov 9:10 AM ET)
Prime Medicine GAAP EPS of -$0.22 beats by $0.02, revenue of $4.21M beats by $3.13M
Seeking Alpha News (Thu, 12-Nov 4:38 PM ET)
Globe Newswire (Thu, 12-Nov 4:15 PM ET)
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Thu, 12-Nov 4:01 PM ET)
Prime Medicine Announces Public Offering Underwriting Agreement
TipRanks (Thu, 12-Nov 9:12 AM ET)
Prime Medicine prices $125M public offering at $3.50 per share
Seeking Alpha News (Wed, 11-Nov 12:36 AM ET)
Prime Medicine Announces Pricing of Public Offering of Common Stock
Globe Newswire (Tue, 10-Nov 9:40 PM ET)
Prime Medicine Updates Corporate Presentation on Gene-Editing Platform
TipRanks (Tue, 10-Nov 4:42 PM ET)
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Prime Medicine trades on the NASDAQ stock market under the symbol PRME.
As of November 13, 2026, PRME stock price climbed to $4.27 with 5,845,389 million shares trading.
PRME has a beta of 1.87, meaning it tends to be more sensitive to market movements. PRME has a correlation of 0.07 to the broad based SPY ETF.
PRME has a market cap of $774.48 million. This is considered a Small Cap stock.
Last quarter Prime Medicine reported $4 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.
In the last 3 years, PRME traded as high as $9.86 and as low as $1.11.
The top ETF exchange traded funds that PRME belongs to (by Net Assets): ARKG, XBI, IWM, VTI, VXF.
PRME has outperformed the market in the last year with a return of +28.2%, while the SPY ETF gained +13.4%. In the last 3 month period, PRME beat the market returning +34.7%, while SPY returned -2.8%. However, in the most recent 2 weeks PRME has underperformed the stock market by returning -9.5%, while SPY returned -0.2%.
PRME support price is $3.61 and resistance is $4.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRME shares will trade within this expected range on the day.
